N/A N=18 Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
Hematologic Malignancies
Primary: Number of Participants With Successful Bone Marrow Engraftment — 1; 15; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=14 Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies
Acute Myeloid Leukemia · Lymphoblastic Leukemia · Acute Leukemia
Primary: Number of Participants With Grade 4 TMI Toxicity — 0; 0; 0; 2 Participants
N/A N=20 Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies
Lymphoma · Leukemia
Primary: Composite Success Rate — 100; 75; 84 Percentage of participants
Phase 2 N=24 Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
Advanced Nonhematological Malignancies · Non-Small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 2 participants
Phase 2 N=27 Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Acute Myelocytic Leukemia · Acute Lymphocytic Leukemia · Chronic Myelogenous Leukemia
Primary: Safety and Tolerability of HSC835 for Clinical Use Were Measured by Infusional Toxicity (Within First 48 Hours After Transplant) and Absence of Graft Failure After 32…
Phase 2 N=25 Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma
Leukemia · Lymphoma, Non-Hodgkin
Primary: Tumor Apoptosis — 7 Participants
Phase 2 N=41 NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Day 100 TRM — 4 Participants
N/A N=160 Patient-Centered Care for the Older Adult With Hematologic Malignancy
Hematologic Malignancy
Primary: Overall Survival — 79; 49 Participants
Phase 2 N=12 Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS
Acute Myeloid Leukemia · Higher Risk Myelodysplastic Syndrome
Primary: Stage 1: Dosing Schedule of Low-dose Cyclophosphamide — 6; 6 Participants
Phase 2 N=87 Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Hematologic Malignancies
Primary: Number of Participants Who Have Severe Acute Graft-versus-host-disease (GVHD) — 2; 0; 5; 1 Participants
Phase 2 N=82 Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
Leukemia · Lymphoma
Primary: Number of Transplant Recipients With Successful Engraftment — 70 Participants
Phase 1 N=23 A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies
Advanced Non-hematologic Malignancies
Primary: Part 1: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 0; 1 participants
Phase 2 N=25 NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases
Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With Donor Neutrophil Engraftment — 3; 7; 1 Participants
Phase 2 N=34 Reduced Intensity Haploidentical Transplant for Hematological Malignancies
Hematological Malignancies
Primary: Overall Survival at 6 Months Post-transplant in Patients Receiving a Partially-matched Related Donor Allogeneic Transplant After Reduced-intensity Conditioning — 22…
Phase 2 N=15 T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
Cervical Cancer · Renal Cancer · Urothelial Cancer
Primary: Maximum Tolerated Cell Dose (MTD) of Cluster of Differentiation 4 (CD4) Cells Transduced With an Anti-MAGE-A3-DP0401/0402 Restricted (MAGE-A3-DP4) T Cell Receptor and…
Phase 1 N=81 A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
Advanced Nonhematologic Malignancies
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 4; 3; 7; 3 Participants
Early Phase 1 N=10 Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)
Advanced B-cell Lymphoid Malignancies
Primary: Total Number of Adverse Events. — 2 Adverse events
N/A N=36 Non-Myeloablative Allogeneic Stem Cell Transplantation
Lymphoma
Primary: Overall Survival at 100 Days Post Transplant (Number of Surviving Participants) — 16; 19 participants
Phase 2 N=17 Adoptive Transfer of Haplo-identical DLI for AML and MDS
Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Number of Subjects With Unacceptable Toxicity — 1 Participants
Phase 2 N=19 HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
Acute Myeloid Leukemia · Acute Lymphocytic Leukemia · Myelodysplasia
Primary: One-year Survival — 50 percentage of participants
Phase 2 N=20 Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
Recurrent Chronic Lymphocytic Leukemia · Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Follicular Lymphoma
Primary: Best Overall Response Rate (ORR) — 2 Participants
Phase 2 N=4 Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
Myelodysplastic Syndrome · Acute Myeloid Leukemia (AML) · Chronic Myeloid Leukemia (CML)
Primary: Cellular Immune Response — 4 participants
Phase 1 N=80 A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors
Nonhematologic Neoplasms, Advanced
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) Assessed by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Version 4.03…
Phase 2 N=19 CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML
Myelodysplastic Syndromes · Secondary Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose of CD8 Depleted Non-engrafting HLA-mismatched Unrelated Donor Lymphocytes Infusion (NE-DLI) — 5 10^7 CD4 cells/kg
Phase 3 N=80 Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
Leukemia, Hairy Cell
Primary: Percentage of Participants With Durable Complete Response (CR) Assessed by Blinded Independent Central Review — 36.3 Percentage of participants
N/A N=8 Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation
Leukemia, Myeloid, Acute · Leukemia, Lymphoblastic, Acute · Leukemia, Myelocytic, Chronic
Primary: Overall Recipient Survival at 6-month Post-relapse of Disease — 0; 4 participants
Phase 2 N=41 Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
Hematopoietic/Lymphoid Cancer
Primary: Count of Participants That Experience 1 Year Relapse Free Survival After Undergoing Hematopoietic Stem Cell Transplantation (HSCT) Using the Thomas Jefferson University…
N/A N=2 Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
Multiple Myeloma · Amyloidosis
Primary: Number of Participants Without Renal Allograft Rejection at 6 Months Post-transplant — 1 Participants
Phase 2 N=51 Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)
Multiple Myeloma
Primary: Change in Diarrhea as Assessed Per CTCAE v5.0 — 0.00; 0.13; 0.00; 0.13 CTCAE grade
Phase 2 N=62 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Acute Myeloid Leukemia With FLT3/ITD Mutation · Acute Myeloid Leukemia With Gene Mutations · Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM
Primary: Disease-free Survival (DFS) — .5 proportion of participants